<DOC>
	<DOCNO>NCT00429702</DOCNO>
	<brief_summary>RATIONALE : Diphenhydramine , lorazepam , dexamethasone may help lessen prevent nausea vomit patient treated chemotherapy . It yet know whether diphenhydramine , lorazepam , dexamethasone effective standard therapy treat nausea vomit cause chemotherapy . PURPOSE : This randomized phase II trial study diphenhydramine , lorazepam , dexamethasone see well work compare standard therapy treat nausea vomit cause chemotherapy young patient newly diagnose cancer .</brief_summary>
	<brief_title>Diphenhydramine , Lorazepam , Dexamethasone Treating Nausea Vomiting Caused By Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare degree chemotherapy-induced nausea vomiting ( CINV ) pediatric patient newly diagnose cancer treat diphenhydramine hydrochloride , lorazepam , dexamethasone vs standard antiemetic therapy first course emetogenic chemotherapy . Secondary - Compare degree CINV first 3 day completion first course emetogenic chemotherapy patient treat antiemetic regimen . OUTLINE : This randomize , prospective , double-blind , multicenter study . Patients stratify accord emetogenic potential chemotherapy regimen ( high v moderate ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive ondansetron hydrochloride IV twice daily saline IV twice daily begin 30-60 minute prior start chemotherapy . Patients also receive diphenhydramine hydrochloride , lorazepam , dexamethasone continuous infusion pump . - Arm II : Patients receive ondansetron hydrochloride IV twice daily dexamethasone IV twice daily begin 30-60 minute prior start chemotherapy . Patients also receive saline continuous infusion pump . In arm , treatment continue first course chemotherapy . Patients may also receive rescue antiemetic medication control breakthrough nausea emesis . Patients parent complete Adapted Rhodes Index Nausea , Vomiting , Retching- Measured Child/Parent questionnaire begin chemotherapy , twice daily chemotherapy , 3 day completion chemotherapy . PROJECTED ACCRUAL : A total 180 patient accrue study .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>INCLUSION CRITERIA : â‰¥ 8 year age &lt; 19 year age time registration Newly diagnose cancer Chemotherapy naive Scheduled receive moderately highly emetogenic chemotherapy ( nonsteroid contain regimen ) inpatient . ( Refer Appendix IV . In multiple agent regimen , select agent high emetic potential . ) Scheduled placement IV access device ( ) treatment purpose ( allow dedicate line continuous infusion study agent ) Not pregnant lactate EXCLUSION CRITERIA : Prior chemotherapy Central Nervous System disease Stem cell transplant onstudy Outpatient chemotherapy Steroids include chemotherapy regimen Contraindication use dexamethasone ( e.g . diabetes ) Hepatic and/or renal failure Allergic study medication Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>emetic chemotherapy</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>